CE Mark for for the Percept RC rechargeable DBS neurostimulator with BrainSense technology

The smallest and thinnest device on the market, Percept RC is the only rechargeable DBS system with BrainSense sensing technology to be launched in the European Union (EU).

"This development represents a critical step in our journey to transform Brain Modulation through sensing-enabled DBS," said Amaza Reitmeier, Vice President and General Manager for Medtronic Brain Modulation. "We are excited about the potential of Percept RC to provide a comfortable, personalized DBS therapy to those living with Parkinson’s Disease, Essential Tremor and Primary Dystonia. Percept RC is also the only rechargeable neurostimulator approved to serve patients with Epilepsy.”

“In addition to being the smallest DBS device on the market, Percept RC combines proprietary battery technology with our brain-sensing technology. These innovations are the culmination of 30 years of investment in clinical trials and R&D to improve the experience of DBS patients,” said Domenico De Paolis, Vice President Neuromodulation International, which is part of the Neuroscience Portfolio at Medtronic.

Overdrive battery technology provides physicians with flexibility to adjust therapy without impacting battery capacity. With weekly charging, the device has greater than 99% battery capacity at 15 years. Rapid recharging means that patients can charge under normal conditions (from 10% to 90% full) in less than an hour.

The Percept RC neurostimulator will be available in Western Europe beginning mid-December, and will launch in additional regions based on local regulations.

It is also available in Japan and under review by the U.S. Food and Drug Administration.